⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37625 | 1.00 | — | — | |
| SCHEMBL3194607 | 1.00 | — | — | |
| SCHEMBL5991463 | 0.86 | — | — | |
| SCHEMBL13438779 | 0.86 | — | — | |
| SCHEMBL3071586 | 0.84 | CRBN (0.34) | — | |
| SCHEMBL20445551 | 0.82 | KMT2A (0.34) | — | |
| SCHEMBL20444035 | 0.82 | KMT2A (0.34) | — | |
| SCHEMBL7428323 | 0.82 | KMT2A (0.34) | — | |
| SCHEMBL7433757 | 0.82 | KMT2A (0.34) | — | |
| SCHEMBL14928 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1784220-A | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-06-07 | — | — | CN | claimed |
| EP-1620082-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | claimed |
| WO-2004098625-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111315738-B | Inhibitors of glutaminyl cyclase | 维沃永治疗股份公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098513-A2 | NASAL ADMINISTRATION OF THE LH-RH ANALOG LEUPROLIDE | WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040072748-A1 | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections | CENTEGEN, INC. | 2004-04-15 | — | — | US | disclosed |
| CN-1268178-A | Enterococcus faecalis polynucleotides and polypeptides | HUMAN GENOME SCIENCES INC (US) | 2000-09-27 | — | — | CN | disclosed |
| US-5487898-A | PEPTIDES | ABBOTT LABORATORIES (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0469102-B1 | NOVEL PEPTIDE SUBSTRATES, METHOD OF PREPARATION AND USE IN C PROTEIN DETERMINATION | SERBIO (FR) | 1995-03-01 | — | — | EP | disclosed |
| US-5362851-A | Tripeptides | SERBIO (FR) | 1994-11-08 | — | — | US | disclosed |